| 2020-02-26 15:29:57|
CVM 15:29 02/26 02/26/20
CEL-SCI off lows after CEO letter to shareholders
Shares of CEL-SCI, which dropped to as low as $7.20 earlier this afternoon, have rebounded somewhat and are now trading at $9.42 following a letter to shareholders from CEL-SCI CEO Geert Kersten which said that Multikine, which has been in Phase 3 trial since 2011, is likely producing "some kind of a survival benefit." Despite the uptick, shares of CEL-SCI are still down over 42% on the day, having opened at $15.76.